BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35480994)

  • 1. Proviral Integration of Moloney Virus-2 (PIM-2) Expression Level as a Prognostic Marker in Patients with Acute Myeloid Leukemia.
    Hamed G; Omar HM; Sarhan AM; Salah HE
    Int J Gen Med; 2022; 15():4247-4258. PubMed ID: 35480994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.
    Cheng H; Huang C; Xu X; Hu X; Gong S; Tang G; Song X; Zhang W; Wang J; Chen L; Yang J
    J Transl Med; 2017 Aug; 15(1):179. PubMed ID: 28851457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.
    Kapelko-Słowik K; Urbaniak-Kujda D; Wołowiec D; Jaźwiec B; Dybko J; Jakubaszko J; Słowik M; Kuliczkowski K
    Postepy Hig Med Dosw (Online); 2013 Jun; 67():553-9. PubMed ID: 23752607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and Significance of Pim-3 Gene in Acute Myeloid Leukemia].
    Zhou ZC; Tian ZG; Yuan Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):316-20. PubMed ID: 27150984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
    Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
    Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-22 is a novel prognostic marker for acute myeloid leukemia.
    Qu H; Zheng G; Cheng S; Xie W; Liu X; Tao Y; Xie B
    J Clin Lab Anal; 2020 Sep; 34(9):e23370. PubMed ID: 32533562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-gene signature might predict prognosis in patients with acute myeloid leukemia.
    Zhu X; Zhao Q; Su X; Ke J; Yi Y; Yi J; Lin J; Qian J; Deng Z
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32436945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
    Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
    Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.
    Yang DQ; Zhou JD; Wang YX; Deng ZQ; Yang J; Yao DM; Qian Z; Yang L; Lin J; Qian J
    Int J Lab Hematol; 2017 Feb; 39(1):42-50. PubMed ID: 27577964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications.
    Abdel Rahman H; Farrag SA; El-Attar IA
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):39-47. PubMed ID: 18839034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.
    El Bordiny M; Al-Ghandour A; Abo Elwafa RA; Fayed O
    Clin Transl Oncol; 2019 Jul; 21(7):864-873. PubMed ID: 30506133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
    Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
    Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudogene BMI1P1 expression as a novel predictor for acute myeloid leukemia development and prognosis.
    Zhou LY; Zhai LL; Yin JY; Vanessa ME; Zhou J; Zhang J; Tang X; Lin J; Qian J; Deng ZQ
    Oncotarget; 2016 Jul; 7(30):47376-47386. PubMed ID: 27329719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia.
    Gaiger A; Schmid D; Heinze G; Linnerth B; Greinix H; Kalhs P; Tisljar K; Priglinger S; Laczika K; Mitterbauer M; Novak M; Mitterbauer G; Mannhalter C; Haas OA; Lechner K; Jäger U
    Leukemia; 1998 Dec; 12(12):1886-94. PubMed ID: 9844919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics.
    Zhang TJ; Zhou JD; Ma JC; Deng ZQ; Qian Z; Yao DM; Yang J; Li XX; Lin J; Qian J
    Clin Chem Lab Med; 2017 Jan; 55(1):123-131. PubMed ID: 27305704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.